Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$75.17 USD

75.17
6,687,807

+0.14 (0.19%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $75.17 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 21% (198 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Astrazeneca (AZN) Advances But Underperforms Market: Key Facts

In the closing of the recent trading day, Astrazeneca (AZN) stood at $64.60, denoting a +0.69% change from the preceding trading day.

The Zacks Analyst Blog Highlights Costco Wholesale, The Walt Disney, AstraZeneca, O'Reilly Automotive and Restaurant Brands International

Costco Wholesale, The Walt Disney, AstraZeneca, O'Reilly Automotive and Restaurant Brands International are part of the Zacks top Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Costco, Walt Disney & AstraZeneca

Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), The Walt Disney Company (DIS) and AstraZeneca PLC (AZN).

Kinjel Shah headshot

Pharma Stock Roundup: FDA Priority Tag to SNY, ABBV Filings, CHMP Nod for AZN, JNJ, MRK

The FDA grants priority review status to Sanofi's (SNY) and AbbVie's (ABBV) sBLAs for Dupixent and Epkinly, respectively

Fusion (FUSN) to Report Q4 Earnings: Here's What to Expect

Investor focus is likely to be on updates regarding Fusion Pharmaceuticals' (FUSN) pipeline candidates on the fourth-quarter conference call.

AstraZeneca PLC (AZN) is Attracting Investor Attention: Here is What You Should Know

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Kinjel Shah headshot

Pharma Stock Roundup: Pfizer's Velsipity Receives EU Nod, ABBV Gets New CEO & More

European Commission approves Pfizer's (PFE) Velsipity ulcerative colitis (UC) pill. AbbVie (ABBV) appoints Robert A. Michael as the new CEO.

Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y

Ionis (IONS) incurs a narrower-than-expected fourth-quarter loss. Sales beat estimates. Higher R&D revenues push top-line growth.

Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally

Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.

Ionis' (IONS) Olezarsen Gets FDA's Orphan Tag for Rare Disease

FDA grants orphan drug status to Ionis' (IONS) olezarsen for treating familial chylomicronemia syndrome (FCS). An NDA for olezarsen is expected to be filed this year.

AstraZeneca PLC (AZN) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Astrazeneca (AZN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Ionis' (IONS) Eplontersen Gets Fast Track Tag for New Indication

The FDA bestows a Fast Track designation to Ionis (IONS) and partner AstraZeneca's (AZN) eplontersen for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Kinjel Shah headshot

Pharma Stock Roundup: AZN & LLY's Q4 Earnings, NVO, NVS & MRK's M&A Deals

Eli Lilly (LLY) and AstraZeneca (AZN) announce fourth-quarter results. Novo Nordisk (NVO), Merck (MRK) and Novartis (NVS) make M&A announcements.

Astrazeneca (AZN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Jobless Claims Decreased More Than Expected

Jobless Claims Decreased More Than Expected

Mark Vickery headshot

Jobless Claims Steady; Mixed Q4 for AZN, HSY and PM

We're once again reassured that employment, on a finer week-over-week scale, is not falling off a cliff.

AstraZeneca (AZN) Q4 Earnings & Sales Miss Estimates, Stock Down

AstraZeneca (AZN) marginally misses fourth-quarter estimates for earnings and sales. It expects revenues and EPS to increase at a low double-digit to low teens percentage in 2024 at CER.

Amgen (AMGN) Q4 Earnings Top, Horizon Drugs Drive Sales

Amgen (AMGN) beats fourth-quarter estimates for earnings and sales. Horizon's products add $954 million in sales in the quarter.

Astrazeneca (AZN) Q4 Earnings Preview: What You Should Know Beyond the Headline Estimates

Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

AstraZeneca (AZN) to Report Q4 Earnings: Here's What to Expect

Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View

Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance. Stock rises in pre-market.

Sanofi (SNY) Misses on Q4 Earnings and Sales, Stock Down

Sanofi (SNY) misses fourth-quarter estimates for earnings and sales. It maintains 2024 earnings growth guidance.

Astrazeneca (AZN) Stock Moves -0.83%: What You Should Know

Astrazeneca (AZN) closed the most recent trading day at $66.64, moving -0.83% from the previous trading session.